{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.797"},{"groupId":"OG001","value":"0.306"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"261"},{"groupId":"OG001","value":"257"}],"units":"Participants"}],"description":"The proportion of patient by arm that experienced grade 3 or higher adverse events will be reported","groups":[{"description":"Palbociclib 125 mg daily and AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestratnt)","id":"OG000","title":"Arm A"},{"description":"AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestrant)","id":"OG001","title":"Arm B"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"24 months","title":"Incidence of Grade 3 or Higher Adverse Events (as Graded by NCI CTCAE v 4.0)","type":"SECONDARY","unitOfMeasure":"proportion of participants"}